Latest Pharma Insights
Wave Surges As Obesity Candidate Cuts Fat And Spares Muscle
WVE-007 could be a "powerful disruptor" to the existing obesity market, says the company, which is set to raise $250m to fund its Phase II studies.
Scrip - December 9, 2025
WVE-007 could be a "powerful disruptor" to the existing obesity market, says the company, which is set to raise $250m to fund its Phase II studies.
Scrip - December 9, 2025
Kymera Keeps Rising With More Positive Dupixent-In-A-Pill Data
Early atopic dermatitis data on the oral STAT6 degrader helps the US firm’s hopes of matching the Sanofi and Regeneron injectable blockbuster on efficacy.
Scrip - December 9, 2025
Early atopic dermatitis data on the oral STAT6 degrader helps the US firm’s hopes of matching the Sanofi and Regeneron injectable blockbuster on efficacy.
Scrip - December 9, 2025
People On The Move: Appointments At Stada, Nestlé, CMA
A round-up of the latest people moves: Stada names general counsel; Nestlé announces departures; CMA elects board members.
HBW Insight - December 9, 2025
A round-up of the latest people moves: Stada names general counsel; Nestlé announces departures; CMA elects board members.
HBW Insight - December 9, 2025
AAM Urges ‘Steady Leadership’ At FDA Following Pazdur’s Abrupt Resignation
With Richard Pazdur’s abrupt exit marking the fifth CDER leadership change in a year, the AAM is urging continuity and stability amid the ongoing turbulence.
Generics Bulletin - December 9, 2025
With Richard Pazdur’s abrupt exit marking the fifth CDER leadership change in a year, the AAM is urging continuity and stability amid the ongoing turbulence.
Generics Bulletin - December 9, 2025
ASH: Kelonia Presents Early Data Giving Boost To In Vivo CAR-T
The company presented data on four patients as a late-breaking abstract at the American Society of Hematology meeting.
Scrip - December 9, 2025
The company presented data on four patients as a late-breaking abstract at the American Society of Hematology meeting.
Scrip - December 9, 2025
Belgian Regulator Presses Roche Further Over Biosimilar Abuse Allegations
The Belgian Competition Authority has confirmed that it is escalating a complaint against Roche over alleged strategies used to delay biosimilar competition to rituximab and trastuzumab.
Generics Bulletin - December 9, 2025
The Belgian Competition Authority has confirmed that it is escalating a complaint against Roche over alleged strategies used to delay biosimilar competition to rituximab and trastuzumab.
Generics Bulletin - December 9, 2025
Stock Watch: Just One Reason Not To Invest
An investment only becomes appealing when all the ducks are in a row; if just one duck strays, investors can sense trouble and may hesitate before proceeding.
Scrip - December 9, 2025
An investment only becomes appealing when all the ducks are in a row; if just one duck strays, investors can sense trouble and may hesitate before proceeding.
Scrip - December 9, 2025
ASH: Lilly’s Jaypirca Looks Headed For The Front Line
Data from the Phase III BRUIN CLL-313 trial presented at ASH showed clear superiority for the non-covalent BTK inhibitor as a single agent compared with bendamustine/rituximab.
Scrip - December 9, 2025
Data from the Phase III BRUIN CLL-313 trial presented at ASH showed clear superiority for the non-covalent BTK inhibitor as a single agent compared with bendamustine/rituximab.
Scrip - December 9, 2025
Hopewell Told Delay Is ‘Of Its Own Making’ As Cladribine Stay-Lifting Bid Fails
Delaware district court refuses to shorten 30-month stay, leaving Hopewell unable to launch its generic Mavenclad product.
Generics Bulletin - December 9, 2025
Delaware district court refuses to shorten 30-month stay, leaving Hopewell unable to launch its generic Mavenclad product.
Generics Bulletin - December 9, 2025
Biocon-BBL Integration: Can It Unmask The Biosimilars Arm’s Intrinsic Worth?
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Generics Bulletin - December 9, 2025
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Generics Bulletin - December 9, 2025
ASH: InnoCare Upbeat About BCL2 Inhibitor Mesutoclax In MCL
InnoCare talks to Scrip about the plans and potential benefits for its BCL2 inhibitor mesutoclax in mantle cell lymphoma and beyond as it presents new results at ASH, as BeOne’s contender sonrontoclax also moves ahead in the same indication.
Scrip - December 9, 2025
InnoCare talks to Scrip about the plans and potential benefits for its BCL2 inhibitor mesutoclax in mantle cell lymphoma and beyond as it presents new results at ASH, as BeOne’s contender sonrontoclax also moves ahead in the same indication.
Scrip - December 9, 2025
Galway Medtech Incubators Nurture Next-Gen Innovators
Start-up medtech firms in the west of Ireland can benefit from incubator programs at two of the region’s universities, which support innovators across the medical device and digital health industries from concept to multi-employee businesses.
Medtech Insight - December 9, 2025
Start-up medtech firms in the west of Ireland can benefit from incubator programs at two of the region’s universities, which support innovators across the medical device and digital health industries from concept to multi-employee businesses.
Medtech Insight - December 9, 2025
Global Medtech Guidance Tracker: November 2025
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 50 documents have been posted on the tracker since its last update.
Medtech Insight - December 9, 2025
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 50 documents have been posted on the tracker since its last update.
Medtech Insight - December 9, 2025
Freenome Goes Public In $330M SPAC, Shares Early Data For Next-Gen CRC Blood Test
Freenome will combine with Perceptive Capital Solutions Corp in a SPAC deal worth $330m. The goal is to advance Freenome’s blood-based tests for early detection of cancer and, in 2026, launch its advanced colorectal cancer detection test SimpleScreen, currently under FDA review.
Medtech Insight - December 9, 2025
Freenome will combine with Perceptive Capital Solutions Corp in a SPAC deal worth $330m. The goal is to advance Freenome’s blood-based tests for early detection of cancer and, in 2026, launch its advanced colorectal cancer detection test SimpleScreen, currently under FDA review.
Medtech Insight - December 9, 2025
Potential US Exit From USMCA Would Place $10.1Bn Cosmetics Sector At Risk – PCPC
The North American cosmetics sector would face major supply-chain and regulatory risks if USMCA is not renewed, says PCPC, which encouraged the US Trade Representative during a Dec. 5 hearing to keep the agreement and its Cosmetics Annex in place as it prepares its Jan. 2 recommendation to Congress.
HBW Insight - December 9, 2025
The North American cosmetics sector would face major supply-chain and regulatory risks if USMCA is not renewed, says PCPC, which encouraged the US Trade Representative during a Dec. 5 hearing to keep the agreement and its Cosmetics Annex in place as it prepares its Jan. 2 recommendation to Congress.
HBW Insight - December 9, 2025
Wave Surges As Obesity Candidate Cuts Fat And Spares Muscle
WVE-007 could be a "powerful disruptor" to the existing obesity market, says the company, which is set to raise $250m to fund its Phase II studies.
Scrip - December 9, 2025
WVE-007 could be a "powerful disruptor" to the existing obesity market, says the company, which is set to raise $250m to fund its Phase II studies.
Scrip - December 9, 2025
Kymera Keeps Rising With More Positive Dupixent-In-A-Pill Data
Early atopic dermatitis data on the oral STAT6 degrader helps the US firm’s hopes of matching the Sanofi and Regeneron injectable blockbuster on efficacy.
Scrip - December 9, 2025
Early atopic dermatitis data on the oral STAT6 degrader helps the US firm’s hopes of matching the Sanofi and Regeneron injectable blockbuster on efficacy.
Scrip - December 9, 2025
ASH: Kelonia Presents Early Data Giving Boost To In Vivo CAR-T
The company presented data on four patients as a late-breaking abstract at the American Society of Hematology meeting.
Scrip - December 9, 2025
The company presented data on four patients as a late-breaking abstract at the American Society of Hematology meeting.
Scrip - December 9, 2025
Stock Watch: Just One Reason Not To Invest
An investment only becomes appealing when all the ducks are in a row; if just one duck strays, investors can sense trouble and may hesitate before proceeding.
Scrip - December 9, 2025
An investment only becomes appealing when all the ducks are in a row; if just one duck strays, investors can sense trouble and may hesitate before proceeding.
Scrip - December 9, 2025
ASH: Lilly’s Jaypirca Looks Headed For The Front Line
Data from the Phase III BRUIN CLL-313 trial presented at ASH showed clear superiority for the non-covalent BTK inhibitor as a single agent compared with bendamustine/rituximab.
Scrip - December 9, 2025
Data from the Phase III BRUIN CLL-313 trial presented at ASH showed clear superiority for the non-covalent BTK inhibitor as a single agent compared with bendamustine/rituximab.
Scrip - December 9, 2025
ASH: InnoCare Upbeat About BCL2 Inhibitor Mesutoclax In MCL
InnoCare talks to Scrip about the plans and potential benefits for its BCL2 inhibitor mesutoclax in mantle cell lymphoma and beyond as it presents new results at ASH, as BeOne’s contender sonrontoclax also moves ahead in the same indication.
Scrip - December 9, 2025
InnoCare talks to Scrip about the plans and potential benefits for its BCL2 inhibitor mesutoclax in mantle cell lymphoma and beyond as it presents new results at ASH, as BeOne’s contender sonrontoclax also moves ahead in the same indication.
Scrip - December 9, 2025
Galway Medtech Incubators Nurture Next-Gen Innovators
Start-up medtech firms in the west of Ireland can benefit from incubator programs at two of the region’s universities, which support innovators across the medical device and digital health industries from concept to multi-employee businesses.
Medtech Insight - December 9, 2025
Start-up medtech firms in the west of Ireland can benefit from incubator programs at two of the region’s universities, which support innovators across the medical device and digital health industries from concept to multi-employee businesses.
Medtech Insight - December 9, 2025
Global Medtech Guidance Tracker: November 2025
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 50 documents have been posted on the tracker since its last update.
Medtech Insight - December 9, 2025
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 50 documents have been posted on the tracker since its last update.
Medtech Insight - December 9, 2025
Freenome Goes Public In $330M SPAC, Shares Early Data For Next-Gen CRC Blood Test
Freenome will combine with Perceptive Capital Solutions Corp in a SPAC deal worth $330m. The goal is to advance Freenome’s blood-based tests for early detection of cancer and, in 2026, launch its advanced colorectal cancer detection test SimpleScreen, currently under FDA review.
Medtech Insight - December 9, 2025
Freenome will combine with Perceptive Capital Solutions Corp in a SPAC deal worth $330m. The goal is to advance Freenome’s blood-based tests for early detection of cancer and, in 2026, launch its advanced colorectal cancer detection test SimpleScreen, currently under FDA review.
Medtech Insight - December 9, 2025
People On The Move: Appointments At Stada, Nestlé, CMA
A round-up of the latest people moves: Stada names general counsel; Nestlé announces departures; CMA elects board members.
HBW Insight - December 9, 2025
A round-up of the latest people moves: Stada names general counsel; Nestlé announces departures; CMA elects board members.
HBW Insight - December 9, 2025
Potential US Exit From USMCA Would Place $10.1Bn Cosmetics Sector At Risk – PCPC
The North American cosmetics sector would face major supply-chain and regulatory risks if USMCA is not renewed, says PCPC, which encouraged the US Trade Representative during a Dec. 5 hearing to keep the agreement and its Cosmetics Annex in place as it prepares its Jan. 2 recommendation to Congress.
HBW Insight - December 9, 2025
The North American cosmetics sector would face major supply-chain and regulatory risks if USMCA is not renewed, says PCPC, which encouraged the US Trade Representative during a Dec. 5 hearing to keep the agreement and its Cosmetics Annex in place as it prepares its Jan. 2 recommendation to Congress.
HBW Insight - December 9, 2025
AAM Urges ‘Steady Leadership’ At FDA Following Pazdur’s Abrupt Resignation
With Richard Pazdur’s abrupt exit marking the fifth CDER leadership change in a year, the AAM is urging continuity and stability amid the ongoing turbulence.
Generics Bulletin - December 9, 2025
With Richard Pazdur’s abrupt exit marking the fifth CDER leadership change in a year, the AAM is urging continuity and stability amid the ongoing turbulence.
Generics Bulletin - December 9, 2025
Belgian Regulator Presses Roche Further Over Biosimilar Abuse Allegations
The Belgian Competition Authority has confirmed that it is escalating a complaint against Roche over alleged strategies used to delay biosimilar competition to rituximab and trastuzumab.
Generics Bulletin - December 9, 2025
The Belgian Competition Authority has confirmed that it is escalating a complaint against Roche over alleged strategies used to delay biosimilar competition to rituximab and trastuzumab.
Generics Bulletin - December 9, 2025
Hopewell Told Delay Is ‘Of Its Own Making’ As Cladribine Stay-Lifting Bid Fails
Delaware district court refuses to shorten 30-month stay, leaving Hopewell unable to launch its generic Mavenclad product.
Generics Bulletin - December 9, 2025
Delaware district court refuses to shorten 30-month stay, leaving Hopewell unable to launch its generic Mavenclad product.
Generics Bulletin - December 9, 2025
Biocon-BBL Integration: Can It Unmask The Biosimilars Arm’s Intrinsic Worth?
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Generics Bulletin - December 9, 2025
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Generics Bulletin - December 9, 2025
Wherever Medtech Goes, AI Will Have One Hand On The Steering Wheel
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
In Vivo - December 8, 2025
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
In Vivo - December 8, 2025
Biopharma In 2026: From Darwinian Reset To Disciplined Growth
The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.
In Vivo - December 8, 2025
The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.
In Vivo - December 8, 2025
As Lilly And Novo Nordisk Grow Their Obesity Empires, What Comes Next?
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.
In Vivo - December 8, 2025
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.
In Vivo - December 8, 2025